У нас вы можете посмотреть бесплатно Using artificial intelligence to estimate overall mortality and non-relapse mortality after alloSCT или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
In this video, Alberto Mussetti, MD, Catalan Institute of Oncology, Barcelona, Spain, discusses the results of a study which evaluated the use of artificial intelligence (AI) to estimate overall mortality and non-relapse mortality following allogeneic stem cell transplantation (alloSCT) in patients with hematological malignancies. Although AI methodology represents a powerful tool to risk stratify patients, the results demonstrated poor accuracy, and prognosis was not improved. This highlights the importance of using high quality data where all clinical and biological variables are included. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.